What Комбифлокс Treats: Main Uses and Benefits

The primary therapeutic benefit of Комбифлокс is its use in providing support for conditions involving heightened symptoms that are typically complex, involving more than one class of pathogen. By addressing these multiple microbial causes simultaneously, the medication offers support that helps ease the overall symptom burden and supports general well-being during symptomatic phases. This combination is considered relevant for managing symptoms associated with diarrhea of mixed infection in adults, and may also be used for infections of the female reproductive system and pelvic area.

This dual-action approach is relevant in clinical settings that involve acute or unstable symptom patterns, such as infectious diarrheal illness, acute dysentery, and infections of the female reproductive system and pelvic area (including PID). Applied in these challenging symptomatic phases, it provides support that assists in easing the discomfort and associated symptoms related to irritative states.

Quick Fact: Relief for Acute Distress
The combination is applied when symptoms create noticeable physiological strain associated with mixed bacterial and protozoal infection of the digestive tract.

Regulatory References

1. NAFDAC Summary of Product Characteristics for Ofloxacin and Ornidazole

This medicine is an antimicrobial combination (Ofloxacin and Ornidazole) with a highly restricted eligibility profile, primarily for use in adults only. The restrictions are strictly defined in official regulatory documents.

Contraindicated Populations

Use of Комбифлокс is contraindicated (absolutely prohibited) for the following groups:

• Children and growing adolescents.
• Pregnant and breastfeeding women.
• Persons with known hypersensitivity to either ofloxacin, ornidazole, or any other quinolone or nitroimidazole agent.
• Patients with a history of tendon disorders related to previous fluoroquinolone use.
• Patients with epilepsy or an existing Central Nervous System (CNS) disorder associated with a lowered seizure threshold.
• Patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) activity.

Conditional Use and Restrictions

For eligible adults, use requires caution or modification in certain health states:

• Renal Impairment: Requires dose adjustment for the ofloxacin component based on kidney function.
• Severe Hepatic Impairment: Use with caution; the dose may need to be reduced due to slower excretion.
• Older Adults: Patients over 60 years of age are at an increased risk of tendinitis and tendon rupture.
• Specific Comorbidities: Use requires careful monitoring in diabetic patients (due to risk of dysglycaemia) and is avoided in patients with a history of Myasthenia Gravis.

Interaction Map: Interactions with other medicines and products — official regulatory information for Комбифлокс

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Anticoagulants (Vitamin K Antagonists), Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Systemic Corticosteroids, Agents prolonging the QT interval, Antidiabetic Agents, Antacids, and Iron/Zinc Preparations.
Specific interacting medicines (if explicitly listed)	Warfarin, Theophylline, Cimetidine, Glibenclamide, Phenobarbital, Phenytoin, Lithium, Sucralfate, Vecuronium Bromide.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic reinforcement (CNS toxicity, QTc risk); Competition for renal tubular secretion (decreased clearance); Absorption interference (chelation/binding); Altered half-life and plasma clearance.
Timing-based interaction rules (if applicable)	Antacids, Iron/Zinc salts, and Sucralfate must be administered at least two hours before or two hours after Ofloxacin administration to prevent reduced absorption.
Population-specific interaction notes (if applicable)	Elderly patients and concurrent Corticosteroid users have a heightened risk of tendon injury/rupture; Diabetic patients on antidiabetic therapy have an increased risk of dysglycemia.
Interaction-related restrictions	Alcohol (Ethanol) must not be consumed during treatment or for a minimum of 3 days after discontinuing the medicine.

---

Interaction classifications (high-level)

Classification	Description (as defined in official documents)
Interaction severity classification (as defined in official documents)	Contraindicated Combination (Alcohol/Ethanol), Clinically Significant Interaction (Anticoagulants, QTc agents, CNS sensitizers, Absorption interference).
Regulatory basis (EMA / FDA / etc.)	Information derived from SmPC (Summary of Product Characteristics) and FDA Prescribing Information.
Interaction-context constraints (as defined in official documents)	Time separation required for absorption interferents; Mandatory prohibition (Alcohol); Increased vigilance for specific patient populations.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with Theophylline or certain NSAIDs is documented to lower the cerebral seizure threshold and increase CNS risk.
• The combination with Systemic Corticosteroids is associated with an increased risk of tendinitis/tendon rupture and aortic aneurysm/dissection.
• The effect of Vitamin K Antagonists (e.g., Warfarin) is officially potentiated, increasing the risk of bleeding.
• Cimetidine and other agents can decrease the clearance of Ofloxacin and Ornidazole, resulting in increased plasma concentrations of both components.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define this product's interaction structure based on both Pharmacodynamic reinforcement of serious risks, such as cardiac QTc prolongation and CNS excitability, and Pharmacokinetic alteration of drug exposure and clearance. These formal statements establish mandatory time-separation constraints for mineral-containing agents and non-negotiable substance prohibitions, strictly delimiting co-administration practices based on officially documented outcomes.

The action of Комбифлокс is defined by a dual, complementary mechanism that targets the fundamental processes required for the survival and reproduction of susceptible pathogens.

Inhibition of Bacterial DNA Synthesis Machinery

The Ofloxacin component acts on the bacterial DNA replication pathway. It targets and blocks two essential bacterial enzymes, DNA Gyrase and Topoisomerase IV, by stabilizing the enzyme-DNA complex and preventing the necessary re-sealing of the DNA strand. The resulting accumulation of irreversible DNA double-strand breaks leads directly to bacterial cell death, which is the resulting physiological change linked to this mechanism.

Chemical Disruption of Anaerobic and Protozoal DNA

The Ornidazole component is activated within specific microbes that thrive in low-oxygen environments. It is reduced by microbial enzymes into highly cytotoxic free radicals that indiscriminately chemically damage the microbial DNA and other critical macromolecules. This destructive molecular cascade results in the rapid cidal (killing) effect against protozoa and obligate anaerobic bacteria, which results in the elimination of these specific microbial types.

Mechanistic Complementarity for Broadened Scope

The two active ingredients maintain mechanistic complementarity, allowing for the addressing of distinct microbial populations. By simultaneously employing two different strategies—enzyme inhibition and chemical radical destruction—the drug results in the simultaneous elimination of a wide spectrum of susceptible mixed bacterial and parasitic pathogens.

How to Use Комбифлокс

The usage of Комбифлокс, a fixed-dose combination of Ofloxacin 200 mg and Ornidazole 500 mg, is determined by specific procedural guidelines outlined in prescribing information. The medication is primarily intended for oral administration.

---

Official Administration Guidelines

Instruction	Detail
Route and Form	Oral use, typically as a film-coated tablet for adults. A lower-strength oral suspension may be available for pediatric administration.
Dosing Schedule	The standard adult dose is one tablet (200 mg Ofloxacin/500 mg Ornidazole) per administration. The course duration typically ranges from 5 to 10 days.
Frequency Pattern	The standard regimen is administered twice daily (B.I.D.).
Intake Conditions	The tablet should be taken with sufficient fluid. To prevent a reduction in absorption, instructions mandate that the dose be separated by at least two hours from products containing polyvalent cations, such as antacids, sucralfate, iron, calcium, or zinc supplements.

---

Population-Specific Use

Prescribing guidelines include instructions for dose modification based on the patient's organ function. For patients with severe hepatic impairment (liver dysfunction), the standard dosing interval must be doubled. Furthermore, for patients with renal impairment (kidney dysfunction) with a Creatinine Clearance ≤ 50 ml/min, the dosage of the Ofloxacin component specifically requires adjustment according to established guidelines. The full course of treatment, as defined by the prescribed duration, must be completed.

Research Evidence / Overview of Studies

This section summarizes key research findings on Drug X.

---

Clinical Efficacy Studies

Research has investigated the possibility that Drug X influences inflammatory markers, which is one factor studied in relation to chronic pain.

Key Trial Data: Condition A

Clinical trials have evaluated the possible effect of Drug X on the quality of life for patients with Condition A.

• Primary Endpoint: A key study measured pain scores over a 12-week period. This study compared the change in flare-up management in the Drug X group versus the placebo group.
• Secondary Outcomes: Studies examined whether the use of Drug X was associated with changes in pain and fatigue in subjects.
• Response Rate: The observed response rate was assessed over a period of six months in subjects receiving Drug X compared to those receiving a control.

Combination Therapy Trials

Research explored whether findings suggested a link between the combined use of agents and patient compliance and adherence to therapy.

• One study evaluated the use of Drug X alongside Agent Z in subjects with Condition B.
• The study evaluated the safety profile of the agent as studied in adults.
• Studies have evaluated the effects of combining Drug X with Treatment Y, including the potential for side effects.

---

Safety and Tolerability

Research evaluated the overall safety profile of Drug X across various trials.

• Common Side Effects: The most frequently reported adverse events included mild headache, nausea, and localized injection site reactions. These effects were noted to diminish in study subjects.
• Serious Adverse Events (SAE): The study recorded the rate of serious adverse events.
• Future Directions in Research: Further research continues to explore long-term outcomes. Ongoing trials are investigating new research areas for Drug X.

Common questions about Комбифлокс (FAQ)

Q: Why is Комбифлокс not prescribed for viral illnesses like the common cold?

This medicine is classified as a combination antibacterial and antiprotozoal agent. According to official guidelines, antibiotics are only effective against infections caused by susceptible bacteria and certain parasites. The drug is not effective against viral infections, such as the common cold, the flu, or most sore throats.

---

Q: How quickly does Комбифлокс typically start working for an infection?

Regulatory guidelines indicate that symptom improvement is generally anticipated during the course of treatment. The full effectiveness of the antibiotic course is achieved by completing the prescribed duration. If symptoms do not improve or worsen, seeking professional guidance is indicated by official instructions.

---

Q: Can Комбифлокс cause sensitivity to sunlight?

Yes, the Ofloxacin component has been associated with an increased sensitivity to sunlight, a reaction known as phototoxicity. Regulatory information describes the need to avoid exposure to direct or artificial ultraviolet light while the medicine is in use. The use of protective clothing and sunscreen is generally noted in official guidance.

---

Q: What is the difference between the brand name and generic version of Комбифлокс?

A generic version contains the same active ingredients (Ofloxacin and Ornidazole) as the brand-name product. Regulatory agencies, such as the FDA, require generic drugs to meet the exact same strict standards for quality, strength, purity, and dosage as the original brand-name medicine.

---

Q: Is it common to experience dizziness when taking Комбифлокс?

Regulatory documentation lists dizziness as a commonly reported potential side effect associated with the fluoroquinolone component of this medicine. Other frequently reported adverse events include mild headache and nausea.

---

Q: Does Комбифлокс affect a person's driving ability or focus?

Official product information notes that the medicine may cause central nervous system side effects such as dizziness, confusion, or visual disturbances. Official instructions state that patients must be informed of how they react to the medication before performing tasks that require concentration, such as driving or operating machinery.

---

Q: What are the signs of a potential liver problem described in the safety information for Комбифлокс?

Regulatory safety information lists specific signs that require immediate medical attention if they are noticed. These signs may include the yellowing of the skin or eyes (jaundice), unusually dark urine, or unexplained stomach pain.

---

Q: Does the official prescribing information contain a section on drug resistance?

Yes, the official prescribing information for the antibiotic component contains warnings related to antimicrobial stewardship. Regulatory documents emphasize the importance of using the drug appropriately to reduce the development of drug-resistant bacteria and maintain effectiveness.

---

Q: Can side effects of Комбифлокс occur after the medicine has been completely finished?

Yes, regulatory safety warnings indicate that some serious adverse reactions can occur with a delayed onset. Official information explicitly states that certain effects, such as tendon damage (tendon rupture), can occur not only during treatment but also several months after stopping the use of the medicine.

---

Q: Are there specific recommendations about hydration while taking Комбифлокс?

The official administration guidelines require taking the tablet with sufficient fluid for proper intake. However, there are no specific, mandated hydration rules beyond this requirement. General health guidance suggests maintaining adequate fluid intake, unless a healthcare professional has provided specific limitations.

---

Q: What does the evidence say about the potential for Комбифлокс to cause vision changes?

Official safety documentation for this drug class includes impaired or blurred vision as a reported potential side effect. Regulatory sources outline that discontinuing treatment and seeking professional guidance is warranted if changes to vision are experienced.

---

Q: Are there specific food products mentioned that should be avoided or separated from Комбифлокс?

Official prescribing information mandates that this medicine be separated by at least two hours from any products containing polyvalent cations, such as iron, calcium, or zinc supplements. This separation is necessary to prevent a reduction in the drug's absorption. The need for caution is noted when consuming mineral-fortified foods.

---

Q: Is Комбифлокс a drug that carries a Black Box Warning from the FDA or equivalent agency?

Yes, the fluoroquinolone component (Ofloxacin) is subject to a boxed warning issued by major regulatory agencies. This warning highlights the potential risk of serious, disabling, and potentially permanent adverse reactions. These reactions involve multiple body systems, including the tendons, nerves, muscles, and central nervous system.

---

Q: Why is the risk of C. difficile-associated diarrhea specifically mentioned with antibiotics like Комбифлокс?

Official safety documentation confirms the risk of severe diarrhea caused by Clostridium difficile infection (CDAD). This happens because antibiotics can disrupt the natural balance of beneficial bacteria in the gut. The resulting overgrowth of C. difficile allows it to produce toxins that cause infection.

Official Storage and Disposal Profile

The storage and disposal instructions for this prescription product are governed by regulatory guidelines to maintain safety and efficacy.

Storage Requirements:

Classification	Requirement
Container Security	Keep the medicine in its original container and secure the safety lock if applicable.
Child Protection	Store in a place strictly out of the sight and reach of children and pets.
Stability	Always check the product's expiration date; unused or expired medication must be disposed of promptly.

Disposal Rules:

1. The primary method for disposal is using an authorized drug take-back program or mail-back envelope.
2. If take-back options are unavailable, mix the medicine with an unappealing substance (like coffee grounds or dirt) and place the mixture in a sealed container before discarding in the household trash.
3. Do not flush the medicine down the toilet or sink unless explicitly instructed to do so by the manufacturer's labeling.